Cepheid $538.58 M in annual revenue in FY 2015. See insights on Cepheid including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Improving patient outcomes is the primary goal of any diagnostic system. But our GeneXpert ® family of systems have set a new standard in workflow flexibility, 24/7 testing accuracy, and user-friendly design — delivered in an astonishingly beautiful and compact package.

Clarke, was considered one of the 'Big Three' science-fiction writers during his lifetime. Robbie by isaac asimov pdf. Heinlein and Arthur C.

One of contemporary gospel music's brightest and most enduring stars, singer, songwriter, and producer Kirk Franklin emerged in the early '90s leading the Texas-based choir the Family, whose platinum-selling 1993 debut, Kirk Franklin & the Family, proved not only to be a chart-topping gospel success, but crossed over to the R&B and pop charts as well. Kirk franklin christmas album.

1. User Manual System
2. Cepheid Genexpert User Manual 2017

1. View and Download GeneXpert Xpert MTB RIF user manual online. Semi-quantitative nested real-time PCR in-vitro diagnostic test. Xpert MTB RIF Medical Equipment pdf.
2. DESCRIPTION OF Xpert™ MTB TEST The Xpert TB assay performed on the Cepheid GeneXpert Dx system is a rapid test for the detection of M. Tuberculosis (MTB) and rifampicin resistance. The Xpert™ MTB test The assay is based on multiplex, nested real-time PCR.
3. The XPert comes with up to four serial ports for connection to satellite, modem, a PC, the Internet, etc. In addition, every unit comes with a minimum of two megabytes of RAM for data storage. All inputs to the systems can be found at the bottom side of the unit, as shown below. The XPert requires power from an external battery of 9.5-16 VDC.

The Xpert MTB/RIF is a cartridge-based nucleic acid amplification test (NAAT) for simultaneous rapid tuberculosis diagnosis and rapid antibiotic sensitivity test. It is an automated diagnostic test that can identify Mycobacterium tuberculosis (MTB) DNA and resistance to rifampicin (RIF). It was co-developed by the laboratory of Professor David Alland at the University of Medicine and Dentistry of New Jersey (UMDNJ).^[1] Cepheid Inc. and Foundation for Innovative New Diagnostics, with additional financial support from the US National Institutes of Health (NIH).

User Manual System

In December 2010, the World Health Organization (WHO) endorsed the Xpert MTB/RIF for use in TB endemic countries.^[2] This followed 18 months of assessment of its field effectiveness in TB, MDR-TB and TB/HIV co-infection.^[3]This test, and others that are likely to follow, could have the potential to improve the diagnosis of TB in those that are likely to be missed by traditional tests.^[3][4]

The CDC said in 2015^[5] that the Xpert MTB/RIF test was 'revolutionizing tuberculosis (TB) control by contributing to the rapid diagnosis of TB disease and drug resistance. The test simultaneously detects Mycobacterium tuberculosis complex (MTBC) and resistance to rifampin (RIF) in less than 2 hours. In comparison, standard cultures can take 2 to 6 weeks for MTBC to grow and conventional drug resistance tests can add 3 more weeks.'^[5]

Background[edit]

Tuberculosis is one of the deadliest public health threats today. Traditionally, tuberculosis is mostly being diagnosed by a combination of chest X-rays, the staining of sputum with special dyes followed by microscopy, the growth of Mycobacterium tuberculosis in culture and the Mantoux test. The sputum smear microscopy is easy to do and is very cheap and combined with chest X-rays has been used for a long time by TB control agencies worldwide. However the sputum smear microscopy(sputum AFB ) test has some problems in HIV-positive patients and children, as well as patients with low bacterial load.The Xpert MTB/RIF test exhibits high sensitivity and specificity for detecting pulmonary TB disease. An in vitro study demonstrated a limit of detection of as few as 131 colony-forming units/mL of MTB, compared with approximately 10,000 colony-forming units/mL with conventional smear microscopy.^[1][6] Drug susceptibility could only be diagnosed from the growth of Mycobacterium tuberculosis in culture which can take as long as six weeks and needs high bio safety labs and is costly. The determination of drug susceptibility is particularly relevant because Mycobacterium tuberculosis becomes increasingly resistant to two of the major anti-tuberculosis drugs, isoniazide and rifampicin. This form of tuberculosis is called multi-drug-resistant tuberculosis (MDR-TB) is rapidly on the rise globally. MDR-TB cases need different antibiotics and are more difficult to treat owing to higher costs of drugs and longer regimens .

How the test works[edit]

The Xpert MTB/RIF detects DNA sequences specific for Mycobacterium tuberculosis and rifampicin resistance by polymerase chain reaction^[4][7] It is based on the Cepheid GeneXpert system, a rapid, simple-to-use nucleic acid amplification tests (NAAT). The Xpert® MTB/RIF purifies and concentrates Mycobacterium tuberculosis bacilli from sputum samples, isolates genomic material from the captured bacteria by sonication and subsequently amplifies the genomic DNA by PCR. The process identifies most of the clinically relevant Rifampicin resistance inducing mutations in the RNA polymerase beta (rpoB) gene in the Mycobacterium tuberculosis genome in a real time format using fluorescent probes called molecular beacons. Results are obtained from unprocessed sputum samples in 90 minutes, with minimal biohazard and very little technical training required to operate.^[8] This test was developed as an on-demand near patient technology which could be performed even in a doctor's office if necessary.

A review to assess the diagnostic accuracy of Xpert TB found that when used as an initial test to replace smear microscopy it had pooled sensitivity of 89% and specificity of 99% . However, when Xpert TB was used as an add-on for cases of negative smear microscopy the sensitivity was only 67% and specificity 99%.^{[9][needs update]} In a clinical study conducted the sensitivity of the MTB/RIF test on just 1 sputum sample was 92.2% for culture-positive TB; 98.2% for smear+ and culture-positive cases; and 72.5% for smear-negative, culture-positive cases, with a specificity of 99.2%. Sensitivity and higher specificity were slightly higher when 3 samples were tested^[10]

Cost[edit]

Some concerns have been raised about the Xpert MTB/RIF, including minor operational issues and cost. The concessional price for a GeneXpert system is currently USD 32,000 for a four module instrument. As of 6 August 2012, the cost of a test cartridge in countries eligible for concessional pricing is USD 9.98.^[11] As of 30 June 2013, 1,402 GeneXpert systems (comprising 7553 modules) and >3 million Xpert MTB/RIF cartridges had been procured in 88 of the 145 countries under concessional pricing.^[12]

Cepheid Genexpert User Manual 2017

References[edit]

1. ^ ^ab'Frequently asked questions on Xpert MTB/RIF assay' Retrieved on 12 June 2012
2. ^'WHO endorses new rapid tuberculosis test' 8 December 2010. Retrieved on 12 June 2012
3. ^ ^abSmall, P. M., Pai, M. (2010) 'Tuberculosis diagnosis - time for a game change' N. Engl. J. Med. 363: 1070-1071
4. ^ ^abVan Rie, A., Page-Shipp, L., Scott, L., Sanne, I., Stevens, W. (2010) 'Xpert® MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope?' Expert Rev. Mol. Diagn. 10: 937-946
5. ^ ^abCenters for Disease Control and Prevention (2015), 'A New Tool to Diagnose Tuberculosis: The Xpert MTB/RIF Assay'(PDF), CDC website, archived from the original(PDF) on 2017-12-17, retrieved 2018-05-25.
6. ^'A New Era: Molecular Tuberculosis Diagnosis'.
7. ^Helb, D., et al (2010) 'Rapid detection of Mycobacterium tuberculosis and Rifampin resistance by use of on-demand, near-patient technology. J. Clin. Microbiol. 48: 229-237
8. ^Boehme, C. C., et al. (2010) 'Rapid molecular detection of tuberculosis and rifampin resistance' N. Engl. J. Med. 363: 1005-1015
9. ^Steingart, KR; Schiller, I; Horne, DJ; Pai, M; Boehme, CC; Dendukuri, N (21 January 2014). 'Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults'. The Cochrane Database of Systematic Reviews. 1 (1): CD009593. doi:10.1002/14651858.CD009593.pub3. PMC4470349. PMID24448973.
10. ^Boehme CC, Nabeta P, Hillemann D, et al. (2010). 'Rapid molecular detection of tuberculosis and rifampin resistance'. N Engl J Med. 363 (11): 1005–1015. doi:10.1056/nejmoa0907847. PMC2947799. PMID20825313.
11. ^'Negotiated prices for Xpert® MTB/RIF and FIND country list'. FIND Diagnostics. FIND. October 2013. Archived from the original on April 7, 2014. Retrieved 6 April 2014.
12. ^'WHO monitoring of Xpert MTB/RIF rollout' World Health Organisation. Retrieved on 1 Sept 2013

External links[edit]